Haematology 2018

Landmark (from EOI) PFS analysis: by antibody arm

PFS for non-CMR vs CMR status using Lugano 2014 criteria (N=508)

1.0

89.5 (84.5, 93.0)

85.7 (79.4, 89.4)

0.8

69.7 (46.5, 84.3)

0.6

41.4 (23.2, 58.8)

0.4

Probability

R-CMR (n=217) G-CMR (n=232) R non-CMR (n=34) G non-CMR (n=25) Censored

0.2

0

0

6

12

18

24

30

36

42

48

54

Time since end of treatment (months)

R-CMR, n=217

G-CMR, n=232

R non-CMR, n=34

G non-CMR, n=25

2.5-year PFS from EOI, % (95% CI)

85.7 (79.4, 89.4)

89.5 (84.5, 93.0)

41.4 (23.2, 58.8)

69.7 (46.5, 84.3)

HR (95% CI)

0.7 (0.4, 1.0); p=0.06

0.5 (0.2, 1.2); p=0.10

Trotman J, et al. ICML 2017